Material and methods
Barrett’s esophagus
The study is a randomized trial and was conducted prospectively in a tertiary care centre in Germany (12/2017–05/2022). All of the endoscopists involved had sufficient experience in interventional Barrett’s esophagus therapy (each having treated over 100 patients with neoplastic Barrett’s esophagus). The study protocol was approved by the General Medical Council of the state of Hesse (FF100/2017) and registered in the German trial registry (DRKS-ID: DRKS00013026).